Patent US4012496A successfully refreshed from Google Patents.
US4012496A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vaginal ring
Assignee: Bayer Pharma AG
•
Filing: 1975-10-17
•
Granted: 1977-03-15
•
Expires: 1995-10-17
Abstract
Abstract A composite vaginal ring containing a safe and effective amount of a pharmaceutically active medicament, which comprises: A. a major supporting vaginal ring consisting essentially of a physiologically acceptable synthetic resin and having at least a portion of the annular surface thereof adapted to mate with corresponding minor, medicament-containing vaginal ring segment; and B. at least one minor, medicament-containing vaginal ring segment adapted to mate with the modified annular surface of said major supporting vaginal ring and consisting essentially of a safe and effective amount of a pharmaceutically active amount of a nonionic, lipophilic drug dissolved or uniformly suspended in an elastomeric, cross-linked LTV linear dimethylpolysiloxane resin.
Inventors
- 👤 Gisela Schopflin
- 👤 Gerhard Laudahn
- 👤 Barbara Muhe
- 👤 Heidemarie Hartmann
- 👤 Fred Windt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:09
CPC Classifications
A; A61; A61M; A61M31/00; A61M31/002; A61F; A61F6/00; A61F6/06; A61F6/08; A61K; A61K9/00; A61K9/0012; A61K9/0034; A61K9/0036
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
148 words
A composite vaginal ring containing a safe and effective amount of a pharmaceutically active medicament, consisting essentially of: a. a supporting, medicament-free vaginal ring consisting essentially of a physiologically acceptable synthetic resin selected from the group consisting of organopolysiloxane elastomers, polyamides, natural and synthetic rubber, polyesters, polytetrafluoroethylene and polyethylenes and having a continuous encircling pocket-like indentation along the outer edge of the annular surface along the central plane thereof adapted to mate with a corresponding smaller, medicament-containing outer encircling annular vaginal ring segment; and b. a smaller, vaginal medicament-containing outer encircling annular vaginal ring adapted to mate with the continuous encircling pocket-like indentation in the modified annular surface of said supporting, medicament-free vaginal ring along the central plane thereof and consisting essentially of a safe and effective amount of a pharmaceutically active nonionic, lipophilic vaginal drug dissolved or uniformly suspended in as elastomeric, cross-linked LTV linear dimethylpolysiloxane resin.
Claim 2
Dependent Claim
148 words
A composite vaginal ring containing a safe and effective amount of a pharmaceutically active medicament, consisting essentially of: a. a supporting, medicament-free vaginal ring consisting essentially of a physiologically acceptable synthetic resin selected from the group consisting of organopolysiloxane elastomers, polyamides, natural and synthetic rubber, polyesters, polytetrafluoroethylene and polyethylenes and having a continuous encircling pocket-like indentation along the outer edge of the annular surface along the central plane thereof adapted to mate with a corresponding smaller, medicament-containing outer encircling annular vaginal ring segment; and b. a smaller, vaginal medicament-containing outer encircling annular vaginal ring adapted to mate with the continuous encircling pocket-like indentation in the modified annular surface of said supporting, medicament-free vaginal ring along the central plane thereof and consisting essentially of a safe and effective amount of a pharmaceutically active nonionic, lipophilic vaginal drug dissolved or uniformly suspended in as elastomeric, cross-linked LTV linear dimethylpolysiloxane resin.
Claim 3
Dependent Claim
19 words
A vaginal ring according to claim 1, wherein said minor ring segment is vulcanized onto said major supporting ring.
Claim 4
Dependent Claim
165 words
A vaginal ring according to claim 1, wherein said LTV resin component consists essentially of a nontoxic pharmaceutical composition adapted for implantation into a human or animal body to provide a constant, uniform drug release rate over a time interval of several months or years, being substantially free of peroxide, acetic acid and metal salts of carboxylic acids and consisting essentially of a homogeneous mixture of: a. 85-95, parts by weight of an LTV linear dimethylpolysiloxane resin containing 0.05-0.5 molar percent of methylvinylsiloxane units, having a molecular weight of 20,000-50,000 and containing an average of 1.58-2.02 monovalent hydrocarbon residues per silicone atom; b. correspondingly 15-5, parts by weight of a cross-linking composition consisting essentially of a dimethylpolysiloxane cross-linking agent substantially free of methylvinylsiloxane units, having a molecular weight of 500-1000 and containing 1-3 Si--H bonds per molecule; c. a catalytic amount of a noble-metal based cross-linking catalyst; and d. a pharmaceutically active amount of a nonionic, lipophilic drug dissolved or uniformly suspended in said composition.
Claim 5
Dependent Claim
57 words
A vaginal ring according to claim 1, wherein said LTV resin component consists essentially of 85-89 parts by weight of component (a); 5-6 parts by weight of component (b); together with 5-10 parts by weight of a dimethylpolysiloxane resin having a molecular weight of 10,000-40,000 and having 0.2-1.5 molar percent methylvinylsiloxane units as an auxiliary cross-linking agent.
Claim 6
Dependent Claim
226 words
A vaginal ring according to claim 1, wherein said LTV resin component consists essentially of a. 20-100 parts by weight of an organopolysiloxane having a viscosity of 500-200,000 centistokes (at 25° C.) and having the general formula ##STR2##wherein R is lower alkyl and/or aryl of up to 10 carbon atoms, and n is an integer from 200-1600; b. 0-50 parts by weight of an organopolysiloxane copolymer consisting essentially of: i. (R') 3 SiO 0 .5 units, ii. (R') 2 (Vi)SiO 0 .5 units, and iii. SiO 2 units, wherein Vi is a vinyl group and R' is a monovalent organic residue which does not contain any unsaturated groups, and at least 50% of R' is methyl, and wherein the ratio of a+b/c is 0.4-1.5 and the ratio of b/c is 0.02-0.5; c. 5-15 parts by weight of an organohydrogen polysiloxane of the general formula R".sub.a H.sub.b SiO.sub.(4-a-b)/2 wherein R" is a monovalent organic residue which has no unsaturated groups, a and b are each positive numbers; the ratio of a:b is 0.5-10; the sum of a+b is 1-2.5; and wherein at least three hydrogen atoms bound to different Si atoms are present per molecule; which component contains 50-500 molar percent, based on the unsaturated end groups in components (a) and (b) of vinyl groups attached to d. a catalytic amount of platinum or a platinum compound.
Claim 7
Dependent Claim
22 words
A vaginal ring according to claim 1, wherein said major supporting ring is composed of an elastomeric, cross-linked LTV linear dimethylpolysiloxane resin.
Claim 8
Dependent Claim
14 words
A vaginal ring according to claim 1, wherein said drug is a steroid hormone.
Claim 9
Dependent Claim
21 words
A vaginal ring according to claim 7, wherein said drug is at least one steroid hormone having progestational or estrogenic activity.
Claim 10
Dependent Claim
16 words
A vaginal ring according to claim 1, wherein the major supporting ring is a closed-cell foam.
Claim 11
Dependent Claim
22 words
A vaginal ring according to claim 9, wherein said major supporting ring is composed of an elastomeric, cross-linked LTV linear dimethylpolysiloxane resin.
Claim 12
Dependent Claim
14 words
A vaginal ring according to claim 1, wherein said drug is an antiprotozoal medicament.
Claim 13
Dependent Claim
20 words
A vaginal ring according to claim 1, wherein the exposed portion of said minor ring segment is circular in cross-section.
Claim 14
Dependent Claim
17 words
A vaginal ring according to claim 12, wherein the entire minor ring segment is circular in cross-section.
References Cited (Backward Citations)
US3527210A
Cited
US3545349A
Cited
US3659597A
Cited
US3911911A
Cited
US3744489A
Cited
US3920805A
Cited
US3805777A
Cited
US3908646A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-03-14 | 1980-09-13 | 1981-03-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-03-14 | 1984-09-13 | 1985-03-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-03-14 | 1988-09-13 | 1989-03-15 | $7700.00 | Window Closed / Lapsed |